LeMaitre Vascular Inc (NASDAQ:LMAT) CEO George W. Lemaitre sold 15,000 shares of LeMaitre Vascular stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $34.55, for a total value of $518,250.00. Following the completion of the sale, the chief executive officer now directly owns 3,225,709 shares of the company’s stock, valued at approximately $111,448,245.95. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of LeMaitre Vascular Inc (NASDAQ LMAT) traded up $0.03 during trading on Wednesday, hitting $36.99. The stock had a trading volume of 66,258 shares, compared to its average volume of 123,768. The stock has a market capitalization of $715.14, a P/E ratio of 43.66, a price-to-earnings-growth ratio of 2.53 and a beta of 0.55. LeMaitre Vascular Inc has a fifty-two week low of $22.95 and a fifty-two week high of $39.88.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. The company had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $26.23 million. During the same period in the previous year, the firm posted $0.13 earnings per share. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. research analysts anticipate that LeMaitre Vascular Inc will post 0.98 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 5th. Stockholders of record on Thursday, March 22nd will be paid a dividend of $0.07 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.06. The ex-dividend date is Wednesday, March 21st. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.76%. LeMaitre Vascular’s dividend payout ratio is currently 25.88%.
Several brokerages recently commented on LMAT. BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research report on Wednesday, February 28th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $33.00 target price on shares of LeMaitre Vascular in a research report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $34.00.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. 361 Capital LLC bought a new position in shares of LeMaitre Vascular during the third quarter valued at approximately $1,973,000. BNP Paribas Arbitrage SA grew its stake in shares of LeMaitre Vascular by 97.6% during the third quarter. BNP Paribas Arbitrage SA now owns 7,405 shares of the medical instruments supplier’s stock valued at $277,000 after buying an additional 3,657 shares during the last quarter. Allianz Asset Management GmbH grew its stake in shares of LeMaitre Vascular by 4.7% during the third quarter. Allianz Asset Management GmbH now owns 321,820 shares of the medical instruments supplier’s stock valued at $12,042,000 after buying an additional 14,306 shares during the last quarter. State Street Corp grew its stake in shares of LeMaitre Vascular by 25.2% during the second quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock valued at $11,951,000 after buying an additional 77,009 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of LeMaitre Vascular by 137.5% during the third quarter. Rhumbline Advisers now owns 58,535 shares of the medical instruments supplier’s stock valued at $2,190,000 after buying an additional 33,891 shares during the last quarter. 72.88% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Insider Selling: LeMaitre Vascular Inc (NASDAQ:LMAT) CEO Sells 15,000 Shares of Stock” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/lemaitre-vascular-inc-lmat-ceo-george-w-lemaitre-sells-15000-shares.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.